
### [NCIT:C9280](http://purl.obolibrary.org/obo/NCIT_C9280)
**Label:** Mediastinal (Thymic) Large B-Cell Lymphoma

**Subclasses:** [NCIT:C8878](http://purl.obolibrary.org/obo/NCIT_C8878) (Stage III Mediastinal (Thymic) Large B-Cell Cell Lymphoma), [NCIT:C8879](http://purl.obolibrary.org/obo/NCIT_C8879) (Stage IV Mediastinal (Thymic) Large B-Cell Cell Lymphoma), [NCIT:C8876](http://purl.obolibrary.org/obo/NCIT_C8876) (Stage I Mediastinal (Thymic) Large B-Cell Cell Lymphoma), [NCIT:C8877](http://purl.obolibrary.org/obo/NCIT_C8877) (Stage II Mediastinal (Thymic) Large B-Cell Cell Lymphoma), [NCIT:C8874](http://purl.obolibrary.org/obo/NCIT_C8874) (Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma), [NCIT:C8875](http://purl.obolibrary.org/obo/NCIT_C8875) (Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma), 

**Class expressions from DL-Learner:**

- [NCIT:C45212](http://purl.obolibrary.org/obo/NCIT_C45212) (PDCD1LG2 Gene Overexpression) 54.17%
- [NCIT:C39715](http://purl.obolibrary.org/obo/NCIT_C39715) (CD30-Positive Neoplastic Cells Present) 54.17%
- [NCIT:C38660](http://purl.obolibrary.org/obo/NCIT_C38660) (Neoplastic Large B-Lymphocyte with Pale Cytoplasm) 54.17%
- [NCIT:C38329](http://purl.obolibrary.org/obo/NCIT_C38329) (Thymic B-Lymphocyte) 54.17%
- [NCIT:C36593](http://purl.obolibrary.org/obo/NCIT_C36593) (Increased NFkappaB Pathway Activation) 54.17%
- [NCIT:C36442](http://purl.obolibrary.org/obo/NCIT_C36442) (Clonal BCL2 Gene Rearrangement) 54.17%
- [NCIT:C36440](http://purl.obolibrary.org/obo/NCIT_C36440) (Gain of Chromosome 9p) 54.17%
- [NCIT:C36103](http://purl.obolibrary.org/obo/NCIT_C36103) (Rapidly Enlarging Mass) 54.17%
- [NCIT:C3396](http://purl.obolibrary.org/obo/NCIT_C3396) (Superior Vena Cava Syndrome) 54.17%
- [NCIT:C13225](http://purl.obolibrary.org/obo/NCIT_C13225) (Chromosome 9) 54.17%
- [NCIT:C132019](http://purl.obolibrary.org/obo/NCIT_C132019) (BCL2 Gene Rearrangement) and [NCIT:C36333](http://purl.obolibrary.org/obo/NCIT_C36333) (Clonal Gene Rearrangement) 54.17%
- Thing 52.25%
- [NCIT:C82325](http://purl.obolibrary.org/obo/NCIT_C82325) (Signaling Pathway Status) 33.03%
- [NCIT:C36162](http://purl.obolibrary.org/obo/NCIT_C36162) (Localized Disease) 33.03%
- [NCIT:C132019](http://purl.obolibrary.org/obo/NCIT_C132019) (BCL2 Gene Rearrangement) 33.03%


